ClinicalTrialsFinder

Alemtuzumab Clinical Trials

15 recruitingDrug
Phase 214Phase 15

Showing 1–15 of 15 trials

Recruiting
Phase 1Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Chronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT05463133
Recruiting
Phase 1Phase 2

Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study

CD40L-HyperIgM Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)1 enrolled1 locationNCT06959771
Recruiting
Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Sickle Cell DiseaseHemoglobinopathiesGraft Failure
Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333
Recruiting
Phase 2

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Dyskeratosis CongenitaFanconi AnemiaMyelodysplastic Syndromes+5 more
Masonic Cancer Center, University of Minnesota48 enrolled1 locationNCT03579875
Recruiting
Phase 1Phase 2

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Idiopathic Pulmonary FibrosisEmphysema or COPD
Paul Szabolcs8 enrolled2 locationsNCT03500731
Recruiting
Phase 1Phase 2

Autologous Stem Cell Transplantation for Crohn's Disease

Crohn's Disease
Paul Szabolcs20 enrolled2 locationsNCT00692939
Recruiting
Phase 2

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Juvenile Rheumatoid Arthritis (JRA)Primary Immunodeficiency (PID)Congenital Bone Marrow Failure Syndromes+4 more
Paul Szabolcs100 enrolled1 locationNCT01962415
Recruiting
Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Dyskeratosis CongenitaFanconi AnemiaBone Marrow Failure+7 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins27 enrolled1 locationNCT04232085
Recruiting

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Multiple Sclerosis
Biogen1,178 enrolled1 locationNCT05688436
Recruiting
Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Interstitial Lung DiseasePulmonary HypertensionSystemic Sclerosis+1 more
Paul Szabolcs8 enrolled3 locationsNCT03630211
Recruiting
Phase 2

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

Sickle Cell Disease
Children's National Research Institute12 enrolled1 locationNCT06358638
Recruiting
Phase 2

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)66 enrolled1 locationNCT04339777
Recruiting
Phase 1Phase 2

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Sickle Cell Anemia
Paul Szabolcs5 enrolled1 locationNCT03653338
Recruiting
Phase 2

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Children's Hospital Medical Center, Cincinnati60 enrolled1 locationNCT05501756
Recruiting
Phase 2

Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354